Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Elastic NV (ESTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Elastic NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Elastic NV trades at $59.95 (market cap $6.26B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.4× Elastic NV's market cap, and Elastic NV is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ESTC | |
|---|---|---|
Market Cap | $39.89B | $6.26B |
Sector | Health | Technology |
52-Week High | $491.22 | $94.47 |
52-Week Low | $278.09 | $43.30 |
Enterprise Value | $38.15B | $5.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Elastic (ESTC) trades at $60.24, down 2.93% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $72.80. The company shows strong revenue growth, improving profitability into 2026, and consistent earnings beats, while recent news highlights leadership in security and observability markets.
The stock presents a growth opportunity with robust fundamentals and positive analyst sentiment, though risks include high valuation multiples, ongoing legal scrutiny, and competitive pressures in the software sector that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
